ContextThe central role of platelet-rich thrombus in the pathogenesis of acute coronary
syndromes (ACSs) is well-known. Glycoprotein IIb/IIIa (Gp IIb/IIIa) receptor antagonists are …

ContextThrombus formation on disrupted atherosclerotic plaque is the major cause of acute
coronary events. Platelet inhibitors are the mainstay of drug therapy to reduce cardiac …

Aims To assess the efficacy of platelet glycoprotein IIb/IIIa inhibitors in patients with acute
coronary syndromes primarily medically managed. Methods and Results We performed a …

Summary Background Platelet glycoprotein IIb/IIIa inhibitors have been shown to reduce
cardiac complications in patients undergoing percutaneous coronary intervention. The …

Background—Glycoprotein (GP) IIb/IIIa receptor blockers prevent life-threatening cardiac
complications in patients with acute coronary syndromes without ST-segment elevation and …

Platelet membrane glycoprotein IIb/IIIa inhibitors, a new class of potent antiplatelet agents,
have been used in the treatment of acute coronary syndromes as well as in the prevention of …

Background—Numerous clinical trials have established the benefits of intravenous
glycoprotein IIb/IIIa inhibition in the management of coronary artery disease. In contrast, the …

The acute ischemic coronary syndromes of unstable angina and non-Q-wave myocardial
infarction are most commonly caused by intracoronary thrombosis at the site of ruptured …

During the last decade, intensive efforts have been made to evaluate the role of the platelet
glycoprotein (GP) IIb/IIIa complex in platelet-mediated thrombus formation. Significant efforts …

Abstract Glycoprotein (GP) IIb/IIIa inhibitors block platelet aggregation, reducing thrombotic
events in acute coronary syndrome. They are most often utilized in patients who likely have …